Evaluation of the Clinical Efficacy of a Novel Palmitoylethanolamide–Equisetum arvense Supplement for the Management of Chronic Pain: Findings from a Prospective Clinical Trial
Open-label, no control groupHumansWith Equisetum arvense (horsetail)
This study tested palmitoylethanolamide together with Equisetum arvense (horsetail). Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Open-label, no control group
- Subjects
- 50 patients with chronic pain enrolled at one centre. 49 completed.
- Dose used in the study
- Tablets with 600 mg of palmitoylethanolamide and 300 mg of Equisetum arvense: two a day for 2 weeks, then one a day for 6 weeks
- Duration
- 8 weeks
- What was measured
- Pain intensity on two rating scales, pain descriptors, patient satisfaction and quality of life
What the authors reported
The authors reported a fall of 3.8 points on the numeric pain rating scale (p < 0.0001) and a 35% rise in the quality of life score. They classed 46 of 49 patients as responders. No adverse events were reported.
Limits of this study
A before-and-after study with no placebo or comparison group, at one centre. The authors name these limits. The funding statement was not visible on the page checked.
Source
Entry checked against the full text at the publisher (MDPI) on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.